<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113888</url>
  </required_header>
  <id_info>
    <org_study_id>CR999-QZWT-IBS-01</org_study_id>
    <nct_id>NCT05113888</nct_id>
  </id_info>
  <brief_title>Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Qizhi Weitong Granules in the Treatment of Abdominal Pain Symptoms in Diarrhea-type Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study are as follows: 1) To evaluate the efficacy and safety of Qizhi&#xD;
      Weitong granules in the treatment of diarrhea-type irritable bowel syndrome (IBS-D);2) To&#xD;
      explore the dosage of Qizhi Weitong Granulesin treatment of IBS-D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study was divided into three groups: Qizhi Weitong granule high-dose group, Qizhi Weitong granule low-dose group and placebo group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abdominal pain intensity</measure>
    <time_frame>Recorded daily by patients from baseline to day56</time_frame>
    <description>the most severe abdominal pain score in the past 24 hours, with a weekly mean decrease of at least 30% from baseline;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of stool characteristics</measure>
    <time_frame>Recorded daily by patients from baseline to day56</time_frame>
    <description>Record daily by symptom diary card.Stools were recorded according to Bristol Stool Chart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of abdominal pain</measure>
    <time_frame>Recorded daily by patients from baseline to day56</time_frame>
    <description>Number of abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS symptom severity scale（IBS-SSS）</measure>
    <time_frame>Baseline and days 14，28，56</time_frame>
    <description>The IBS symptom severity questionnaire consists of four questions on a 100-point scale, with the highest score being 100 and the lowest being 0. The higher the score, the more severe the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS Quality of Life Scale（IBS-QOL）</measure>
    <time_frame>Baseline and days 14，28，56</time_frame>
    <description>The IBS Quality of Life scale has 34 questions, and adopts a five-level scoring system, with the highest score of 4 points and the lowest score of 0 points. The higher the score, the more serious it is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating Anxiety Scale（SAS)</measure>
    <time_frame>baseline and day56</time_frame>
    <description>There are 20 questions in the self-rating anxiety scale, which is graded at four levels, with the highest score being 4 and the lowest score being 1. The higher the score is, the more serious it is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating Depression Scale(SDS)</measure>
    <time_frame>baseline and day56</time_frame>
    <description>There are 20 questions in the Self-rating Depression Scale, which is graded at four levels, with the highest score being 4 and the lowest score being 1. The higher the score is, the more serious it is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergency drug use</measure>
    <time_frame>Emergence，baseline and days 14，28，56</time_frame>
    <description>Subjects may take Piaverium bromide tablets 3-4 tablets per day if they feel unbearable abdominal pain, and increase to 6 tablets per day if necessary.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Qizhi Weitong granules high-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventions：Qizhi Weitong granules Specification: 5.0g/bag，the drug content is equivalent to 2 bags of Qizhi Weitong granules (2.5g/ bag commercially available).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qizhi Weitong granules low-dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>interventions：Qizhi Weitong granules Specification: 5.0g/bag，the drug content is equivalent to 1 bag of Qizhi Weitong granules (2.5g/ bag commercially available).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>interventions：Qizhi Weitong granules placebo Specification: 5.0g/bag，Does not contain effective crude drug ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qizhi weitong granules(High）</intervention_name>
    <description>take orally before meals, 1 bag each time, 3 times a day.</description>
    <arm_group_label>Qizhi Weitong granules high-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Qizhi weitong granules(Low）</intervention_name>
    <description>take orally before meals, 1 bag each time, 3 times a day.</description>
    <arm_group_label>Qizhi Weitong granules low-dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>take orally before meals, 1 bag each time, 3 times a day.</description>
    <arm_group_label>The control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In line with the diagnostic criteria of WESTERN medicine IBS-D;&#xD;
&#xD;
          -  Aged 18-65 (including 18 and 65 years old) years;&#xD;
&#xD;
          -  The mean weekly NRS score for abdominal pain (the most severe in the past 24 hours)&#xD;
             was between 3.0 and 7.0 within the last week, and there were at least 2 days per week&#xD;
             when fecal traits were classified as type 6 or 7;&#xD;
&#xD;
          -  Informed consent, voluntary test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stool number of type 7 according to Bristol Stool Chart, more than 3 times per day;&#xD;
&#xD;
          -  TCM syndrome was diagnosed as deficiency of spleen and kidney Yang syndrome；&#xD;
&#xD;
          -  Patients who took emergency medication (Piveronium bromide tablets) more than the&#xD;
             standard during admission period (more than 2 days per week on average)；&#xD;
&#xD;
          -  Patients who have been diagnosed with organic diseases of digestive system, such as&#xD;
             inflammatory bowel disease, intestinal tuberculosis, intestinal tumor, etc., or are&#xD;
             still complicated with peptic ulcer and infectious diarrhea；&#xD;
&#xD;
          -  Patients with similar symptoms of IBS, such as eosinophilic enteritis, collagenous&#xD;
             enteritis, lactose intolerance, etc.&#xD;
&#xD;
          -  Patients with intestinal diseases of digestive system, such as tuberculous&#xD;
             peritonitis, cirrhosis, chronic pancreatitis, etc.&#xD;
&#xD;
          -  Patients with systemic diseases affecting digestive tract function, such as&#xD;
             hyperthyroidism or hypothyroidism, endometriosis, chronic renal insufficiency,&#xD;
             autoimmune diseases, diabetes, etc.&#xD;
&#xD;
          -  Previous gastrointestinal surgery (except for appendicitis);&#xD;
&#xD;
          -  Patients with serious cardiovascular diseases, serious liver and kidney diseases,&#xD;
             hematopoietic system diseases, tumor, neurological or psychiatric system diseases;&#xD;
&#xD;
          -  Major anxiety (SAS score ≥70) or major depression (SDS Score ≥73);&#xD;
&#xD;
          -  Concomitant drugs affecting gastrointestinal motility and function (prokinetic drugs,&#xD;
             anticholinergic drugs, calcium channel blockers, 5-HT3 receptor antagonists,&#xD;
             antidiarrhea agents, antacids, antidepressants, antianxiety drugs, intestinal&#xD;
             microbiota regulators, antibiotics, etc.) should not be discontinued in the test;&#xD;
&#xD;
          -  Pregnant or lactating women who had a birth plan from enrollment to 3 months after the&#xD;
             end of the trial.&#xD;
&#xD;
          -  Allergic to the test drug emergency drug and its ingredients;&#xD;
&#xD;
          -  Suspected or confirmed history of alcohol or drug abuse;&#xD;
&#xD;
          -  Patients who participated in other clinical trials within 1 month prior to enrollment;&#xD;
&#xD;
          -  Other subjects considered unsuitable for clinical trials by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xudong Tang, professor</last_name>
    <phone>+86 10-62835001</phone>
    <email>txdly@sina.com.cn</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Qizhi Weitong granules</keyword>
  <keyword>Irritable bowel syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

